Last updated: 2026-09-07 21:25:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Anbio Biotechnology (NNNN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $6.47, with a market capitalization of $287.05M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.28 to $51.33. This page covers its latest market performance, valuation, price trends and company information.
$287.05M | |
$6.58 | |
$55.65 | |
$5.18 | |
$6.60 | |
229.87K | |
102.00K | |
-- | |
$51.33 | |
$6.28 | |
-- | |
-- |
Anbio Biotechnology (NNNN) last closed at $6.60 as of 2026-09-04 23:57:00, unchanged from the previous close of $6.60.
During the latest regular trading session, NNNN traded between $5.18 and $55.65, with a volume of 229.87K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Anbio Biotechnology (NNNN) moved from $7.78 to $6.47, representing a decline of 16.90% ($1.32).
The stock traded between $6.28 and $8.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 252.64 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
NNNN is currently trading at $6.47, placing it 0.4% of the way from its 52-week low of $6.28 to its 52-week high of $51.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
| Employees | 27 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Anbio Biotechnology (NNNN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.